Adaptimmune says it's (nearly) ready to head to the FDA with TCR cancer therapy

Six months after an initial reveal at ASCO, Adaptimmune is back in the limelight with new data Thursday. And the company believes it now has enough to go to regulators for what would be the first-ever TCR therapy.